Literature DB >> 11102510

Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells.

V Vogelsberg-Ragaglia1, J Bruce, C Richter-Landsberg, B Zhang, M Hong, J Q Trojanowski, V M Lee.   

Abstract

Multiple tau gene mutations are pathogenic for hereditary frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), with filamentous tau aggregates as the major lesions in the CNS of these patients. Recent studies have shown that bacterially expressed recombinant tau proteins with FTDP-17 missense mutations cause functional impairments, i.e., a reduced ability of mutant tau to bind to or promote the assembly of microtubules. To investigate the biological consequences of FTDP-17 tau mutants and assess their ability to form filamentous aggregates, we engineered Chinese hamster ovary cell lines to stably express tau harboring one or several different FTDP-17 mutations and showed that different tau mutants produced distinct pathological phenotypes. For example, delta K, but not several other single tau mutants (e.g., V337 M, P301L, R406W), developed insoluble amorphous and fibrillar aggregates, whereas a triple tau mutant (VPR) containing V337M, P301L, and R406W substitutions also formed similar aggregates. Furthermore, the aggregates increased in size over time in culture. Significantly, the formation of aggregated delta K and VPR tau protein correlated with reduced affinity of these mutants to bind microtubules. Reduced phosphorylation and altered proteolysis was also observed in R406W and delta K tau mutants. Thus, distinct pathological phenotypes, including the formation of insoluble filamentous tau aggregates, result from the expression of different FTDP-17 tau mutants in transfected Chinese hamster ovary cells and implies that these missense mutations cause diverse neurodegenerative FTDP-17 syndromes by multiple mechanisms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11102510      PMCID: PMC15059          DOI: 10.1091/mbc.11.12.4093

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  42 in total

1.  Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).

Authors:  N Matsumura; T Yamazaki; Y Ihara
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation.

Authors:  R Dayanandan; M Van Slegtenhorst; T G Mack; L Ko; S H Yen; K Leroy; J P Brion; B H Anderton; M Hutton; S Lovestone
Journal:  FEBS Lett       Date:  1999-03-12       Impact factor: 4.124

3.  A distinct familial presenile dementia with a novel missense mutation in the tau gene.

Authors:  M Iijima; T Tabira; P Poorkaj; G D Schellenberg; J Q Trojanowski; V M Lee; M L Schmidt; K Takahashi; T Nabika; T Matsumoto; Y Yamashita; S Yoshioka; H Ishino
Journal:  Neuroreport       Date:  1999-02-25       Impact factor: 1.837

4.  Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17.

Authors:  M Hong; V Zhukareva; V Vogelsberg-Ragaglia; Z Wszolek; L Reed; B I Miller; D H Geschwind; T D Bird; D McKeel; A Goate; J C Morris; K C Wilhelmsen; G D Schellenberg; J Q Trojanowski; V M Lee
Journal:  Science       Date:  1998-12-04       Impact factor: 47.728

5.  Accelerated filament formation from tau protein with specific FTDP-17 missense mutations.

Authors:  P Nacharaju; J Lewis; C Easson; S Yen; J Hackett; M Hutton; S H Yen
Journal:  FEBS Lett       Date:  1999-03-26       Impact factor: 4.124

6.  Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments.

Authors:  M Goedert; R Jakes; R A Crowther
Journal:  FEBS Lett       Date:  1999-05-07       Impact factor: 4.124

7.  High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands.

Authors:  P Rizzu; J C Van Swieten; M Joosse; M Hasegawa; M Stevens; A Tibben; M F Niermeijer; M Hillebrand; R Ravid; B A Oostra; M Goedert; C M van Duijn; P Heutink
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

8.  Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17.

Authors:  L N Clark; P Poorkaj; Z Wszolek; D H Geschwind; Z S Nasreddine; B Miller; D Li; H Payami; F Awert; K Markopoulou; A Andreadis; I D'Souza; V M Lee; L Reed; J Q Trojanowski; V Zhukareva; T Bird; G Schellenberg; K C Wilhelmsen
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

9.  Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements.

Authors:  I D'Souza; P Poorkaj; M Hong; D Nochlin; V M Lee; T D Bird; G D Schellenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease.

Authors:  A Ebneth; R Godemann; K Stamer; S Illenberger; B Trinczek; E Mandelkow
Journal:  J Cell Biol       Date:  1998-11-02       Impact factor: 10.539

View more
  47 in total

Review 1.  Cellular models for tau filament assembly.

Authors:  Li-wen Ko; Michael DeTure; Naruhiko Sahara; Rifki Chihab; Shu-Hui Yen
Journal:  J Mol Neurosci       Date:  2002-12       Impact factor: 3.444

2.  The acetylation of tau inhibits its function and promotes pathological tau aggregation.

Authors:  Todd J Cohen; Jing L Guo; David E Hurtado; Linda K Kwong; Ian P Mills; John Q Trojanowski; Virginia M Y Lee
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

3.  Fragmentation of the Golgi apparatus induced by the overexpression of wild-type and mutant human tau forms in neurons.

Authors:  Dalinda Liazoghli; Sebastien Perreault; Kristina D Micheva; Mylène Desjardins; Nicole Leclerc
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

Review 4.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

5.  Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.

Authors:  Michael DeTure; Li-Wen Ko; Colin Easson; Shu-Hui Yen
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

6.  Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation.

Authors:  Scott A Yuzwa; Xiaoyang Shan; Matthew S Macauley; Thomas Clark; Yuliya Skorobogatko; Keith Vosseller; David J Vocadlo
Journal:  Nat Chem Biol       Date:  2012-02-26       Impact factor: 15.040

7.  Stabilizing the Hsp70-Tau Complex Promotes Turnover in Models of Tauopathy.

Authors:  Zapporah T Young; Jennifer N Rauch; Victoria A Assimon; Umesh K Jinwal; Misol Ahn; Xiaokai Li; Bryan M Dunyak; Atta Ahmad; George A Carlson; Sharan R Srinivasan; Erik R P Zuiderweg; Chad A Dickey; Jason E Gestwicki
Journal:  Cell Chem Biol       Date:  2016-08-04       Impact factor: 8.116

8.  Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  J Neurosci       Date:  2011-05-25       Impact factor: 6.167

9.  Phosphorylation of α-tubulin by protein kinase C stimulates microtubule dynamics in human breast cells.

Authors:  Shatarupa De; Areti Tsimounis; Xiangyu Chen; Susan A Rotenberg
Journal:  Cytoskeleton (Hoboken)       Date:  2014-02-26

10.  Asparagine residue 368 is involved in Alzheimer's disease tau strain-specific aggregation.

Authors:  Shotaro Shimonaka; Shin-Ei Matsumoto; Montasir Elahi; Koichi Ishiguro; Masato Hasegawa; Nobutaka Hattori; Yumiko Motoi
Journal:  J Biol Chem       Date:  2020-08-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.